Bell Investment Advisors’s TG Therapeutics TGTX Stock Holding History

Bell Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37K	Hold	25	–	–	﹤0.01%	1461
2026 Q1	$831	Hold	25	–	–	﹤0.01%	1594
2025 Q4	$746	Sell	25 -8	-24%	-$261	﹤0.01%	1620
2025 Q3	$1.19K	Sell	33 -50	-60%	-$1.65K	﹤0.01%	1515
2025 Q2	$2.99K	Hold	83	–	–	﹤0.01%	1199
2025 Q1	$3.27K	Sell	83 -8	-9%	-$269	﹤0.01%	1105
2024 Q4	$2.74K	Buy	91 +32	+54%	+$918	﹤0.01%	1208
2024 Q3	$1.38K	Sell	59 -62	-51%	-$1.35K	﹤0.01%	1489
2024 Q2	$2.15K	Buy	121 +34	+39%	+$543	﹤0.01%	1320
2024 Q1	$1.32K	Hold	87	–	–	﹤0.01%	1510
2023 Q4	$1.49K	Hold	87	–	–	﹤0.01%	1450
2023 Q3	$728	Hold	87	–	–	﹤0.01%	1661
2023 Q2	$2.16K	Hold	87	–	–	﹤0.01%	1256
2023 Q1	$1.31K	Hold	87	–	–	﹤0.01%	1457
2022 Q4	$1.03K	Buy	+87	New	+$631	﹤0.01%	1576
2021 Q4	–	Sell	-52	Closed	-$2K	–	1942
2021 Q3	$2K	Buy	+52	New	+$1.61K	﹤0.01%	1161

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Bell Investment Advisors's TGTX Position: Q2 2026 in Review

Bell Investment Advisors held its TG Therapeutics (TGTX) position steady in Q2 2026 at 25 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #1461.

Bell Investment Advisors first reported a position in TGTX in Q3 2021 and has held it in 16 quarters since. The position peaked at $3.27K in Q1 2025. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Bell Investment Advisors held 25 shares of TG Therapeutics worth $1.37K as of Q2 2026.
Bell Investment Advisors left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1461 holding.
Bell Investment Advisors first reported a position in TG Therapeutics in Q3 2021 and has held it in 16 quarters since.
Bell Investment Advisors's TG Therapeutics position peaked at $3.27K in Q1 2025.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.